Meet the Team

Hard working fellas behind the scene

Executive Highlights


max bet pokie wins Medical Device and Combination Drug/Device Innovations and Commercialization – Awarded over 30 United States patents for successfully commercialized inventions of novel medical devices, drug delivery systems and drug therapies throughout career. Built strong sales and marketing teams to win leadership market share against much larger and heavily entrenched competitors.

casino royal club  

Industry Leadership – Largely recognized as a leader in the medical device community, providing guidance to customer professional societies such as the Society of Interventional Radiology (SIR) and American College of Phlebology (ACP) in strategic planning and medical practice expansion, as well as industry peer recognition such as being elected the Chairman of the Medical Device Manufacturers Association (MDMA) Board of Directors.


Unparalleled Recognition – Granted an Honorary Fellowship by the Society of Interventional Radiology (SIR), receiving one of ten Honorary Fellowships granted in the 50 year history of the SIR, and one of only three ever granted to a non-physician.  

Business Development – After founding AngioDynamics as a Division of E-Z-EM, Inc., lead the extremely successful tax free spin-off and Initial Public Offering (IPO) of the company in 2004, winning multiple awards for top-performing medtech IPO and public company business performance.

click the following article  

Mergers & Acquisitions – Spearheaded numerous large and small acquisitions; conducted due diligence, led negotiations, integrated operations, and managed strategic relationships through complex transitions diversity in the workplace thesis statement.


One of Mr. Hobbs’ most outstanding achievements was AngioDynamics, Inc. which he founded as a division of a public parent company, E-Z-EM, Inc. (NASDAQ: EZEM) in 1988. In order to unlock the value of AngioDynamics and maximize EZEM shareholder value, in 2004 Mr. Hobbs led a tax-free spin-off and simultaneous IPO, (NASDAQ: ANGO) with AngioDynamics, Inc. becoming the best performing medtech IPO of 2004. As its CEO, Mr. Hobbs continued to grow AngioDynamics into a top performing public company, being recognized in 2005 and 2006 in Business Week as a “Hot 100 Top Growth Company” and in 2006 receiving a #11 ranking in Forbes “Best 200 Small Companies”. Today, AngioDynamics remains a market leader in image guided therapeutic devices, drug delivery devices and combination drug/device products utilized in cardio and peripheral vascular medicine, cosmetic medicine, and oncology, with annual revenues approaching $400 million and over 700 employees.

Subsequent to leaving AngioDynamics, Mr. Hobbs joined both public and private Boards of Directors in the healthcare field, and was repeatedly asked to become the company’s CEO. Most recently, after serving on its Board of Directors for 6 years, Mr. Hobbs was asked to serve as interim President and Chief Executive Officer at Antares Pharma, Inc., (NASDAQ: ATRS) a specialty pharmaceutical company based in Ewing, N.J. Prior to Antares, Mr. Hobbs served on the Board of Directors of Delcath Systems Inc. (NASDAQ: DCTH) for four years, a specialty pharmaceutical and medical device company focused on new and innovative therapies for the treatment of liver cancers, before becoming its President and Chief Executive Officer.

Mr. Hobbs was elected by industry leadership to serve as Chairman of the Board of Directors of the Medical Device Manufacturers Association (MDMA) from 2010 to 2013. He currently serves as Chairman of the Board of Marvao Medical, Inc., a medical technology company based in Galway, Ireland, and serves on the Boards of OraSure Technologies, Inc, (NASDAQ: OSUR) and Harmonics. Mr. Hobbs also provides consulting and business planning services to healthcare companies via his company, Hobbs Medical Ventures, LLC.

In 2006, Mr. Hobbs was given extraordinary recognition by being granted an honorary fellowship in the Society of Interventional Radiology, which was only the third honorary fellowship ever granted a non-physician in the Society’s 50 year history. He received his Bachelor of Science in Plastics Engineering (Biomedical Emphasis) from the University of Massachusetts, Lowell, and in 2010, he was honored by the University with the “Francis Cabot Lowell Award for Outstanding Achievement in Business.


ANTARES PHARMA, INC., (NASDAQ; ATRS), Ewing, NJ August 2009 – January 2016

Director, President & CEO
Antares Pharma is a specialty pharmaceutical company that markets its branded combination drug/device products directly in the United States and develops products for a multitude of pharmaceutical alliance partners. Antares’ business is driven by the continued development of three proprietary auto-injector and pen platforms.

  • Joined the Antares Pharma, Inc. Board of Directors in 2009, and was subsequently asked by the Board to become interim CEO in June 2014.
  • Successfully conceptualized a plan to develop the COO into the CEO successor and executed a seamless CEO transition in January 2016
  • During tenure as CEO, Antares Pharma’s operational performance improved steadily to record levels, all product litigation was settled, and the CEO transition was conducted with the company in a very strong financial situation.


    • Received three of the company’s four FDA approvals during my tenure with company.
    • Raised $48 million in a public offering in May of 2015, placing the company in a robust financial position.
    • Using unique combination drug/device product experience, drove the alignment of the company’s separate drug and medical device quality systems, resulting in one highly efficient and FDA inspection ready consolidated and fully aligned quality system.
    • Spearheaded the creation of the company’s first strategic plan.
    • Invented revolutionary formulation technology (patent pending) intended to optimize previously impractical formulations for auto-injectors.
    • Created “Upstream Marketing” entity to analyze opportunities and identify the most attractive pipeline development programs.
    • Smoothly integrated contract sales organization to create the company’s first ever employee sales force.

    DELCATH SYSTEMS, INC., (NASDAQ; DCTH), New York, NY                  August 2008 – September 2013

    Director, President & CEO
    Delcath’s revolutionary combination drug/device technology, known as Chemosaturation (CS), allows physicians to deliver ultra high doses of anti-cancer drugs to the site of disease without exposing the patient’s entire body to those same toxic levels of drug. Phase 2 and Phase 3 clinical study results from treating various cancers in the liver have confirmed that delivering more drug to the tumor site, and less to the other regions of the body, enhances tumor shrinkage with improved quality of life over systemic cancer therapies.

    • Joined the Delcath Board of Directors in 2008, and was asked by the Board to become CEO in July 2009.
    • Took the company from a team of seven to a fully commercial and manufacturing operation with over 65 employees.
    • Recruited and formed an R & D team that developed proprietary manufacturing processes resulting in crucial product improvements that dramatically improved the safety profile of the therapy.
    • Completed ongoing Phase 3 trial and piloted the filing of the company’s first ever NDA.


    • Raised over $150 million in secondary offerings for Delcath in an extremely challenging public market environment.
    • Within first 6 months as CEO, launched an operations facility to bring manufacturing in-house, increase quality and reduce COGS.
    • Led regulatory approval of CS for sale in Europe, with commercialization initiated there in mid-2012.
    • Subsequently achieved compelling reimbursement in Germany and the UK with other countries still pending.
    • Successfully developed COO into CEO successor and conducted CEO transition subsequent to receiving CRL that required additional Phase 3 trials.

    ANGIODYNAMICS, INC., (NASDAQ: ANGO), Queensbury, NY              1988 – 2009

    Co-Founder, President, CEO, & Director
    Co-founded a very successful public medical device/drug delivery company that designs, develops, manufactures and markets minimally invasive devices for the targeted treatment of cancer and vascular disease. Company went from start up to leadership market share in core products against much larger, heavily entrenched competition.

    Entrepreneurial endeavor of growing the business from a wholly-owned, green field start-up to an international stand-alone profitable public company, with over 600 employees at 4 facilities and fiscal year 2009 revenues of over $200 million.

    • Company focuses on serving the needs of Interventional Radiologists, Interventional Neuroradiologists, Cardiologists, Surgeons, Nephrologists, Oncologists, and Dermatologists, with peripheral and neuro vascular, vascular access and cancer therapy medical devices.
    • Worldwide sales and marketing, with direct sales forces both domestically and outside the USA (OUS), and additional stocking distributors OUS.
    • Conducted extremely successful IPO (NASDAQ symbol ANGO) in May 2004 and completed total tax free spin-off from E- Z-EM, Inc. in October of 2004, dramatically increasing shareholder value and liquidity.


    • ANGO was the best performing medical technology IPO of the class of 2004, earning the top honors in 2005 and 2006.
    • Recognized in Business Week as a “Hot 100 Top Growth Company” for 2005 and 2006.
    • Received a # 11 ranking in Forbes “Best 200 Small Companies” in 2006.
    • “Beat the big guys” – Achieved #1 market share leadership in core products against much larger, heavily entrenched device companies while utilizing a significantly higher average selling price and stressing product performance, service and overall value proposition.
    • During first 4 years as a public company, 4-year revenue growth exceeded 27% per annum, and average annual operating profit growth surpassed 63%.
    • Customer focused, hands on management style, stressing team alignment and empowerment, plan execution and results achievement.
    • Successfully conducted numerous product and company acquisitions and integrations, including a $240 million dollar public company acquisition of RITA Medical Systems (NASDAQ: RITA) in 2007.
    • Frequently recognized as an industry leader through invitations to lecture and faculty membership at numerous international physician meetings, including: Society of Interventional Radiology Annual Meeting (2002, 2005, 2008, 2009), AIM/VEITH Symposium (2000 – 2008), Practical Training in Vascular Interventions – University of Michigan (2004), Dotter Institute Interventional Conference (2005, 2006).
    • Honorary Fellow, Society of Interventional Radiology, inducted April of 2005. One of ten Honorary Fellowships granted in the 34 year history of the Society of Interventional Radiology, and one of three ever granted to a non- physician.
    • Sole member from industry on the SIR (Society of Interventional Radiology) Strategic Planning Committee: 2001 – 2008. Helped to create first strategic plan for Society in 2001.

    E-Z-EM, INC., (NASDAQ: EZEM), Westbury, NY               1988 – 2004

    Senior Vice President – Business Development, Co-founder & President, AngioDynamics, Inc.
    The worldwide leader in gastrointestinal contrast imaging pharmaceutical agents, combination drug/device systems, and medical devices, focusing on serving the needs of Radiologists, Surgeons and Gastroenterologists.

    • Functioned as a senior member of the Leadership Team, advising on business development and strategy.
    • Wrote business plan and gained Board support to fund “green field” start up of AngioDynamics, Inc., as a wholly owned subsidiary.
    • Conducted IPO (NASDAQ symbol ANGO) in May 2004 and completed total tax free spin-off from E-Z-EM, Inc. (NASDAQ: EZEM) in October of 2004, successfully unlocking tremendous shareholder value.
    • E-Z-EM, Inc., subsequently acquired by Bracco Group, a world-wide leader in imaging agents, for $241 million in 2008

    NORTH AMERICAN MEDICAL INSTRUMENTS CORPORATION (NAMIC), Glens Falls, NY                   1985 – 1988

    Vice President of Marketing and Product Development
    Medical Device Company focused on serving the needs of Interventional Cardiologists. Attained worldwide market leadership in Angiographic Manifolds and Control Syringes. Sold to Pfizer in 1992, later sold to Boston Scientific in 1997, and AngioDynamics in 2012.


    • Under direct report to the CEO, managed the Marketing Department, which consisted of Product Managers, Support Staff, and coordinated customer focused Product Development (team of Engineers and Technicians).
    • Doubled company revenues in 3 years through new product introductions and increased market penetration.
    • Successfully planned the company’s IPO during tenure.

    HOBBS MEDICAL, INC., Stafford Springs, CT                   1983– 1985

    Founder, Chairman and CEO
    Secured venture capital funding, founded and developed a profitable medical device firm focusing on trans-endoscopic interventional devices for Gastroenterologists. Sold company in 1985; remains in operation today as a private company:


    • Devised an innovative trans-endoscopic interventional product line to address market needs.
    • Achieved substantial revenue growth through the cultivation of marketing programs and the establishment of a direct sales force of top performers.
    • Led by example, often called the company’s best sales person by members of the sales force.
    • Sold company in 1985 providing investors with solid return.

    COOK INCORPORATED, Bloomington, IN                  1980– 1983

    Product Development Engineer
    Private medical device company with a concentration in Interventional Radiology, Surgery, and Interventional Cardiology specialties. Multi-billion dollar establishment that holds leadership positions in many market segments.


    • Developed the company’s first high pressure angioplasty product line.
    • Conceived and introduced the company’s first Vena Cava Filter, the “Birds Nest Filter.
    • Realized that I strongly preferred customer interactions to that of other engineers, and requested transfer to the Sales and Marketing Department.



    OraSure Technologies, Inc. (NASDAQ: OSUR)     2016 – Present

    • Member Audit and Compensation Committees
    • OraSure Technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. These products include tests for the detection of antibodies to the HIV virus, including the OraQuick® In-Home HIV Test, OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test and the OraSure® HIV-1 Oral Specimen Collection Device, a test for antibodies to the HCV virus, the OraQuick® HCV Rapid Antibody Test, and oral fluid testing solutions for drugs of abuse testing, including Intercept® Oral Fluid Drug Testing System and Q.E.D.® Saliva Alcohol Test.


    Medical Device Manufacturers AssociationMDMA) 2004 – Present

    • Chairman of the Board 2008- June, 2012
    • Chair of the Nominating, Governance and Compensation Committee.
    • The Medical Device Manufacturers Association (MDMA) is a national trade association based in Washington, D.C. that represents independent manufacturers of medical devices, diagnostic products and health care information systems. MDMA seeks to improve the quality of patient care by influencing government policy, encouraging the development of new medical technology, and fostering the availability of beneficial innovative products.
    • Elected to the Executive Committee as Treasurer in 2006. Involved in extensive government lobbying on numerous industry issues such as FDA budget and user fees, gain sharing, and GPO safe harbor reform.


    Marvao Medical Devices, Ltd. 2013 – Present

    • Marvao has developed a potentially game changing platform technology that seeks to dramatically reduce catheter infections by revolutionizing how tunneled catheters are placed and maintained. In initial clinical data comprised of thousands of catheter days, the NexSite tunneling system has demonstrated a zero catheter related blood infection rate, (CRBI) and even more remarkable, NexSite has done this in some of the most challenging applications such as femoral dialysis catheters (which normally have a very high 5-7% CRBI rate). CRBI has risen to be one of the highest profile issues with hospital administrators since it is life threatening, treatment costs are very high but not reimbursed, and reducing the hospital CRBI rate recently became one of the top quality measures that determine each hospital’s across the board reimbursement rate for all of the hospital’s procedures under the new accountable care system. With this in mind, hospital administrators as well as clinicians have placed a very high priority on embracing any new technologies that materially reduce the CRBI rate. The NexSite system can be mated with any tunneled catheter system so it has broad market utility including applications in dialysis and central lines. NexSite Dialysis Catheters very recently received FDA clearance and CE Mark.


    Harmonics Medical, Inc.  2014 – Present

    • Based in Toronto at Sunnybrook Health Science Center, Founded and Chaired by Kullervo Hynynen, (often called “The Father of HIFU”), Harmonics is developing ultrasound guided high intensity focused ultrasound (HIFU) for a variety of applications. Current HIFU can be a very effective, non-invasive therapy, but suffers tremendous limitations due to the requirement to be used under MR guidance. This ties up a very expensive MR unit for long periods of time which makes HIFU logistically challenging, and very expensive. Using Harmonics’ proprietary ultrasound guidance makes HIFU eminently more practical and opens up a multitude of potential applications.


    Antares Pharma, Inc. (NASDAQ: ATRS) 2009 – 2016

    • Member Audit and Governance Committees until accepting interim CEO position in June 2014.
    • Antares Pharma is committed to developing and commercializing novel combination drug/device products utilizing the company’s unique, advanced drug delivery systems. Antares products are patient focused: they typically improve safety and efficacy, reduce side effects and enable delivery at a lower dose. Their advanced drug delivery systems are also well positioned for “life cycle extension” options in conjunction with strategic alliance partners.


    Morris Innovative, Inc. 2013 – 2015

      Morris Innovative has developed and is commercializing two vascular closure device systems. CombiClose is a very unique combination working sheath/closure sheath system. The FISH ControlClose was very recently introduced procedure ending exchange system that delivers greatly simplified use, and shorter clinician learning curve. Both systems have multiple unique features and benefits that highly differentiate them from the competition. Morris has sold over 30,000 systems in the US so far, and recently received CE Mark approval, so the technology is very well proven.


    Delcath Systems Inc. (NASDAQ: DCTH)    2008 – 2013

    • Member Audit and Nominating and Governance Committees until accepting CEO position in July 2009.
    • The Company’s technology, known as CHEMOSAT or Percutaneous Hepatic Perfusion (PHP), allows physicians to deliver significantly higher doses of chemotherapy to the site of disease without exposing the patient’s entire body to those same potent levels of drug. Initial clinical results from studies treating cancer in the liver confirm that delivering more drug to the tumor site, and less to the other regions of the body, enhances tumor shrinkage with improved quality of life over systemic cancer therapies. CHEMOSAT is approved in the European Union for a broad range of liver cancers and commercial operations commenced in April 2012 with compelling reimbursement established in Germany and the UK in 2015. CHEMOSAT is currently pursuing FDA approval for the indication of melanoma metastases of the liver and is planning to initiate its second Phase 3 clinical trial in the near future.


    Cappella Cardiovascular Systems, Inc. 2009 – 2013

    • Chairman of the Board
    • Early commercial stage, venture capital backed company with a unique solution to treating coronary artery side branch disease.


    Sentinelle Medical Inc. 2008 – 2010

    • Sentinelle Medical Inc., established in 2004, is a private company based in Toronto, Canada and affiliated with Sunnybrook Health Science Center that provides a suite of very high performance MR coils, and software solutions for GE, Toshiba and Siemens, providing health care providers with a fully integrated breast imaging and treatment planning system that result in the highest quality of patient care. Company achieved profitability and positive cash flow in Q4 2008. Achieved very successful exit for investors upon sale of company to Hologic in 2010.


    AngioDynamics, Inc. (NASDAQ: ANGO) 1988 – 2009

    • Co-founder and Vice Chairman of the Board


    AngioDynamics, Ltd. UK 2008 – 2009

    • The European subsidiary and manufacturing facility of AngioDynamics, Inc. based in Cambridge, UK.
    • Obtained as a result of the acquisition of the assets of Diomed, Inc. (AMEX Symbol: DIO) in June of 2008.


    American College of Phlebology Foundation 2006 – 2009

    • Founding member of charitable scientific research and education foundation established in collaboration with its parent medical specialty society, American College of Phlebology, for the purpose of advancing the treatment of venous disease through research and education.
    • Assisted in the creation of the society’s first Strategic Plan.
    • Numerous committee memberships


     Society of Interventional Radiology Foundation    2002 – 2008

    • Charitable scientific research and education foundation established in collaboration with its parent medical specialty society, Society of Interventional Radiology, for the purpose of advancing interventional radiology through research and education.
    • Sole Industry member of the Board; numerous committee positions held throughout tenure.


     AngioDynamics, Ltd., Ireland 1996 – 2001

    • The European subsidiary and cardiovascular products manufacturing facility of AngioDynamics, Inc. based in Enniscorthy, County Wexford, Ireland. Sold to management in 2001 due to strategic decision to exit coronary stent market, becoming ClearStream Technologies, Ltd. Went public on the London Stock Exchange in 2002.


    LeoCor, Inc 1996 – 1999

    • A Texas based cardiovascular medical device technology company ultimately acquired by AngioDynamics, Inc.